[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Corbus Pharmaceuticals Hldgs Inc (CRBP)

Corbus Pharmaceuticals Hldgs Inc (CRBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 210,293
  • Shares Outstanding, K 18,528
  • Annual Sales, $ 0 K
  • Annual Income, $ -78,540 K
  • EBIT $ -90 M
  • EBITDA $ -91 M
  • 60-Month Beta 2.68
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.66

Options Overview Details

View History
  • Implied Volatility 92.42% (-53.10%)
  • Historical Volatility 129.03%
  • IV Percentile 4%
  • IV Rank 4.88%
  • IV High 489.47% on 02/20/26
  • IV Low 72.04% on 05/29/25
  • Expected Move (DTE 23) 1.36 (17.19%)
  • Put/Call Vol Ratio 0.04
  • Today's Volume 22,925
  • Volume Avg (30-Day) 2,184
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 23,601
  • Open Int (30-Day) 21,933
  • Expected Range 6.55 to 9.27

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.30
  • Number of Estimates 6
  • High Estimate $-1.24
  • Low Estimate $-1.38
  • Prior Year $-1.44
  • Growth Rate Est. (year over year) +9.72%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.73 +2.33%
on 05/26/26
12.88 -38.59%
on 05/22/26
-2.15 (-21.37%)
since 04/24/26
3-Month
7.68 +2.99%
on 03/05/26
12.88 -38.59%
on 05/22/26
-0.34 (-4.12%)
since 02/26/26
52-Week
6.72 +17.71%
on 07/01/25
20.56 -61.53%
on 10/20/25
+0.51 (+6.89%)
since 05/23/25

Most Recent Stories

More News
Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers

Data affirms Corbus strategy of targeting tumor types with elevated Nectin-4 expression and clear unmet medical needs while providing an attractive commercial path forward Confirmed ORR of 42.9% observed...

CRBP : 7.91 (-30.31%)
Corbus Pharmaceuticals Teases Key ASCO Cancer Data, Late-Summer Obesity Readout

Corbus Pharmaceuticals (NASDAQ:CRBP) Chief Executive Officer Yuval Cohen said investors should expect more mature clinical updates for CRB-701 at the upcoming ASCO meeting, including the first durability...

CRBP : 7.91 (-30.31%)
Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call

NORWOOD, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity,...

CRBP : 7.91 (-30.31%)
Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors

NORWOOD, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity,...

CRBP : 7.91 (-30.31%)
IPSC : 2.17 (-3.98%)
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences

NORWOOD, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity,...

CRBP : 7.91 (-30.31%)
Corbus Pharmaceuticals: Q1 Earnings Snapshot

Corbus Pharmaceuticals: Q1 Earnings Snapshot

CRBP : 7.91 (-30.31%)
Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update

Reached broad alignment with the FDA on the registration path for CRB-701 for 2L treatment in head and neck squamous cell carcinoma (HNSCC) and cervical cancer with CRB-701 Announced presentation of updated...

CRBP : 7.91 (-30.31%)
Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026

NORWOOD, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on promising new therapies in oncology and obesity, today announced...

CRBP : 7.91 (-30.31%)
Corbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701

NORWOOD, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on promising new therapies in oncology and obesity, today announced...

CRBP : 7.91 (-30.31%)
Corbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity

On track to complete 16-week, dose-finding Phase 1b study (n=240) in summer 2026 Phase 1b data will build upon Phase 1a findings that demonstrated weight loss of nearly 3% at 14 days in individuals...

CRBP : 7.91 (-30.31%)

Business Summary

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic...

See More

Key Turning Points

3rd Resistance Point 14.02
2nd Resistance Point 13.45
1st Resistance Point 12.40
Last Price 7.91
1st Support Level 10.78
2nd Support Level 10.21
3rd Support Level 9.16

See More

52-Week High 20.56
Fibonacci 61.8% 15.27
Fibonacci 50% 13.64
Fibonacci 38.2% 12.01
Last Price 7.91
52-Week Low 6.72

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.